What happened

Shares of Geron (NASDAQ:GERN) were trading up by 35.8% as of 11:33 a.m. EDT on Friday. The big jump came after the company published data from its phase 2 clinical study evaluating imetelstat as a treatment for myelofibrosis, a rare type of bone marrow cancer.

So what

Geron's latest results were published in the Journal of Clinical Oncology. Patients in the phase 2 study who had poor outcomes with previous treatments experienced several clinical benefits after treatment with imetelstat, including improvements in symptoms and increased overall survival.

Scientist looking through a microscope.

Image source: Getty Images.

The biotech stock skyrocketed Friday because investors think that Geron's latest data bodes well for imetelstat's chances of success in late-stage testing. The company is currently evaluating the experimental drug in two phase 3 studies, one targeting myelofibrosis and another targeting myelodysplastic syndromes (MDS), a group of rare bone marrow disorders.

Now what

Geron expects to complete enrollment in its phase 3 study of imetelstat in treating MDS in the second half of this year. Top-line results from the study could be announced as early as late 2022. Geron anticipates an interim analysis from its late-stage study targeting myelofibrosis in 2024.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.